DescriptionSources: https://www.drugs.com/mmx/diapid.htmlCurator's Comment: description was created based on several sources, including
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=016755
Sources: https://www.drugs.com/mmx/diapid.html
Curator's Comment: description was created based on several sources, including
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=016755
Lypressin is synthetic analog of porcine antidiuretic hormone vasopressin. Itis a cyclic nonapeptide that differs from Arg-vasopressin by one amino acid, containing Lys at residue 8 instead of Arg. Lypressin-containing nasal spray was used to treat diabetes insipidus, but its marketing by Sandoz (Novartis) was discontinued.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363078 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8393786 |
7.3 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | DIAPID Approved UseIncreases water reabsorption in the kidney by increasing the cellular permeability of the collecting ducts, resulting in an increase in urine osmolality with a concurrent decrease in urine output. Lypressin is indicated for the prevention or control of polydipsia, polyuria, and dehydration associated with central diabetes insipidus caused by insufficient antidiuretic hormone. |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/mmx/diapid.html
Adults: lypressin spray (diapid) contains contains approximately 0.007 mg lypression per spray. (equivalent to 2 Posterior Pituitary Units). For treatment of diabetes insipidus, 1-2 sprays should be administered in each nostril 4 times daily.
Route of Administration:
Nasal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8393786
V2[Lys8]VP-receptor was transfected into COS7 cells. The displacement experiments were performed with 10 nM [3H] [Arg8]VP in the presence of 0.1 - 10000 nM lypressin. Incubation was performed for 30 min at 30°C in duplicate. Bound ligand was separated from free ligand by filtering the incubation mixture through Whatman GF/B filters soaked in 0.05% bovine serum albumin. Lypressin binds to vasopressin receptor with Ki of 7.3 nM.
Substance Class |
Protein
Created
by
admin
on
Edited
Fri Dec 15 16:07:47 GMT 2023
by
admin
on
Fri Dec 15 16:07:47 GMT 2023
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
7CZF3L922Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C80212
Created by
admin on Fri Dec 15 16:07:47 GMT 2023 , Edited by admin on Fri Dec 15 16:07:47 GMT 2023
|
||
|
WHO-VATC |
QH01BA03
Created by
admin on Fri Dec 15 16:07:47 GMT 2023 , Edited by admin on Fri Dec 15 16:07:47 GMT 2023
|
||
|
WHO-ATC |
H01BA03
Created by
admin on Fri Dec 15 16:07:47 GMT 2023 , Edited by admin on Fri Dec 15 16:07:47 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7CZF3L922Y
Created by
admin on Fri Dec 15 16:07:47 GMT 2023 , Edited by admin on Fri Dec 15 16:07:47 GMT 2023
|
PRIMARY | |||
|
1481
Created by
admin on Fri Dec 15 16:07:47 GMT 2023 , Edited by admin on Fri Dec 15 16:07:47 GMT 2023
|
PRIMARY | |||
|
50-57-7
Created by
admin on Fri Dec 15 16:07:47 GMT 2023 , Edited by admin on Fri Dec 15 16:07:47 GMT 2023
|
PRIMARY | |||
|
C66044
Created by
admin on Fri Dec 15 16:07:47 GMT 2023 , Edited by admin on Fri Dec 15 16:07:47 GMT 2023
|
PRIMARY | |||
|
1711133
Created by
admin on Fri Dec 15 16:07:47 GMT 2023 , Edited by admin on Fri Dec 15 16:07:47 GMT 2023
|
PRIMARY | |||
|
200-050-5
Created by
admin on Fri Dec 15 16:07:47 GMT 2023 , Edited by admin on Fri Dec 15 16:07:47 GMT 2023
|
PRIMARY | |||
|
D008236
Created by
admin on Fri Dec 15 16:07:47 GMT 2023 , Edited by admin on Fri Dec 15 16:07:47 GMT 2023
|
PRIMARY | |||
|
SUB08627MIG
Created by
admin on Fri Dec 15 16:07:47 GMT 2023 , Edited by admin on Fri Dec 15 16:07:47 GMT 2023
|
PRIMARY | |||
|
DTXSID8048575
Created by
admin on Fri Dec 15 16:07:47 GMT 2023 , Edited by admin on Fri Dec 15 16:07:47 GMT 2023
|
PRIMARY | |||
|
m6961
Created by
admin on Fri Dec 15 16:07:47 GMT 2023 , Edited by admin on Fri Dec 15 16:07:47 GMT 2023
|
PRIMARY | Merck Index | ||
|
644076
Created by
admin on Fri Dec 15 16:07:47 GMT 2023 , Edited by admin on Fri Dec 15 16:07:47 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200690
Created by
admin on Fri Dec 15 16:07:47 GMT 2023 , Edited by admin on Fri Dec 15 16:07:47 GMT 2023
|
PRIMARY | |||
|
2959
Created by
admin on Fri Dec 15 16:07:47 GMT 2023 , Edited by admin on Fri Dec 15 16:07:47 GMT 2023
|
PRIMARY | |||
|
DB14642
Created by
admin on Fri Dec 15 16:07:47 GMT 2023 , Edited by admin on Fri Dec 15 16:07:47 GMT 2023
|
PRIMARY | |||
|
6531
Created by
admin on Fri Dec 15 16:07:47 GMT 2023 , Edited by admin on Fri Dec 15 16:07:47 GMT 2023
|
PRIMARY | RxNorm |
From | To |
---|---|
1_1 | 1_6 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE ACTIVE |
IN-VIVO
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Molecular Formula | CHEMICAL |
|
||||
MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|